![Kamran Alam](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kamran Alam
Direttore Finanziario/CFO presso
TAYSHA GENE THERAPIES, INC.
Patrimonio netto: 8 M $ in data 31/05/2026
Profilo
Kamran Alam is currently Chief Financial Officer & Secretary at Taysha Gene Therapies, Inc. since 2020.
Former positions include Chief Financial Officer & Senior Vice President at Rocket Pharmaceuticals, Inc. from 2019 to 2020, Vice President-Finance at Novartis Gene Therapies, Inc. from 2016 to 2019, Senior Director-Finance & Accounting at Aptinyx, Inc. from 2013 to 2016, and Finance Director at Naurex, Inc. Education includes an undergraduate degree from Stephen M.
Ross School of Business and an MBA from Kelley School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 1.341.600 ( 0,49% ) | 8 M $ | 31/05/2026 |
Posizioni attive di Kamran Alam
| Società | Posizione | Inizio |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Direttore Finanziario/CFO | 01/08/2020 |
Precedenti posizioni note di Kamran Alam
| Società | Posizione | Fine |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 01/07/2020 |
| AVEXIS INC | Corporate Officer/Principal | 01/10/2019 |
| APTINYX | Comptroller/Controller/Auditor | 01/04/2016 |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage company, which develops novel therapies | Corporate Officer/Principal | - |
Formazione di Kamran Alam
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
22
Relazioni di 1° grado
7
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage company, which develops novel therapies | Health Technology |
Stephen M. Ross School of Business
 Stephen M. Ross School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
Aptinyx, Inc.
 Aptinyx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies to treat disorders of the brain and nervous system | Health Technology |
Rocket Pharmaceuticals, Inc.
 Rocket Pharmaceuticals, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Taysha Gene Therapies, Inc.
 Taysha Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes adeno-associated viruses-based gene therapies for the treatment of monogenic diseases of the central nervous system | Health Technology |
